Uematsu M, Tarbell N J, Silver B, Coleman C N, Rosenthal D S, Shulman L N, Canellos G, Weinstein H, Mauch P
Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts.
Cancer. 1993 Jul 1;72(1):207-12. doi: 10.1002/1097-0142(19930701)72:1<207::aid-cncr2820720137>3.0.co;2-a.
Patients with Hodgkin disease who have relapses after initial chemotherapy (CT) appear to have a poor prognosis, especially if the duration of the first complete remission (CR) was short. The authors performed a retrospective analysis of patients with Hodgkin disease whose relapse after combination CT was limited to nodal sites; their aim was to study the prognosis of this selected subgroup of patients.
In 28 patients with Hodgkin disease who had relapses in nodal sites after combination CT alone, the disease was restaged carefully to rule out simultaneous extranodal recurrences. Then the patients were treated with wide-field, high-dose radiation therapy (RT) with or without additional CT with curative intent between 1971 and 1987 at the Joint Center for Radiation Therapy. Fourteen patients were in first relapse and were treated with combination CT followed by RT. The remaining 14 patients (8 who were in first relapse and 6 who were in second relapse) were treated with RT alone. RT techniques were similar to those recommended for early-stage disease.
The 7-year actuarial freedom from relapse and survival rates for the patients retreated with CT and RT were 93% and 85%, respectively, as compared with 36% and 36% for patients retreated with RT alone. There was a significant difference for freedom from relapse (P = 0.002) and survival (P = 0.03), favoring patients retreated with both CT and RT.
This retrospective study demonstrates that RT combined with second-line CT can result in a high percentage of durable remissions in patients who have relapses primarily in nodal sites after original treatment with combination CT alone. These durable remissions are seen even in patients who have only a brief CR after initial CT.
霍奇金病患者在初始化疗(CT)后复发,其预后似乎较差,尤其是首次完全缓解(CR)期较短时。作者对霍奇金病患者进行了一项回顾性分析,这些患者在联合CT治疗后复发且局限于淋巴结部位;目的是研究这一特定亚组患者的预后。
28例仅接受联合CT治疗后出现淋巴结部位复发的霍奇金病患者,对疾病进行了仔细的再分期以排除同时存在的结外复发。然后在1971年至1987年期间,这些患者在联合放射治疗中心接受了根治性的广野、高剂量放射治疗(RT),部分患者还接受了额外的CT治疗。14例患者为首次复发,接受联合CT后再行RT治疗。其余14例患者(8例首次复发,6例第二次复发)仅接受RT治疗。RT技术与推荐用于早期疾病的技术相似。
接受CT和RT联合治疗的患者7年无复发生存率和总生存率分别为93%和85%,而仅接受RT治疗的患者分别为36%和36%。在无复发生存率(P = 0.002)和总生存率(P = 0.03)方面存在显著差异,CT和RT联合治疗的患者预后更佳。
这项回顾性研究表明,对于仅接受联合CT初始治疗后主要在淋巴结部位复发的患者,RT联合二线CT治疗可使高比例患者获得持久缓解。即使是在初始CT治疗后CR期较短的患者中也能观察到这些持久缓解。